CVRx, Inc. (CVRX)

CVRx, Inc. (CVRX) Healthcare & Pipeline Overview

CVRx, Inc. focuses on neuromodulation solutions for cardiovascular diseases, primarily through its Barostim device aimed at improving heart failure symptoms. With a direct sales force and international distribution, CVRx operates in the competitive medical device market, addressing a critical need for patients with reduced ejection fraction.

What Is the Investment Thesis for CVRX?

CVRx, Inc. presents a focused investment opportunity within the medical device sector, driven by its Barostim technology targeting heart failure patients. The company's high gross margin of 85.3% indicates strong pricing power and efficient manufacturing. Growth hinges on expanding market penetration in the US and Europe, leveraging its direct sales force and distribution network. Key catalysts include positive clinical trial outcomes and increased adoption by cardiologists. However, the company's negative profit margin of -94.1% highlights the need for improved cost management and scaling of operations to achieve profitability. Investors should monitor revenue growth, regulatory approvals, and competitive pressures within the neuromodulation space.

Based on FMP financials and quantitative analysis

CVRX Key Highlights

• Market capitalization of $149.40M reflects the company's current valuation in the medical device market.
• Gross margin of 85.3% indicates strong pricing power and efficient manufacturing processes.
• Profit margin of -94.1% highlights the company's current challenges in achieving profitability.
• Beta of 1.12 suggests the stock is slightly more volatile than the overall market.
• No dividend is currently offered, indicating a focus on reinvesting earnings for growth.

Who Are CVRX's Competitors?

CVRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CVRX's Key Strengths?

• Proprietary Barostim technology.
• High gross margin.
• Focus on a specific niche within the cardiovascular market.
• Established sales and distribution network in key markets.

What Are CVRX's Weaknesses?

• Negative profit margin.
• Limited product portfolio.
• Reliance on a single product (Barostim).
• Relatively small market capitalization.

What Could Drive CVRX Stock Higher?

• Publication of new clinical data supporting the efficacy of Barostim.
• Expansion of sales and marketing efforts in the United States and Europe.
• Pursuit of regulatory approvals for new indications of Barostim.

What Are the Key Risks for CVRX?

• Financial-distress signal — its Altman Z-Score of -7.12 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies with greater resources.
• Regulatory hurdles and reimbursement challenges affecting market access.
• Dependence on the success of Barostim as the primary revenue driver.
• Negative profit margin and the need to achieve profitability.

What Are the Growth Opportunities for CVRX?

• Expansion in the United States: CVRx has the opportunity to further penetrate the U.S. market by increasing awareness and adoption of Barostim among cardiologists and heart failure specialists. This involves targeted marketing campaigns, clinical education programs, and strategic partnerships with key hospitals and healthcare systems. The U.S. market for heart failure devices is substantial, driven by a large and aging population with a high prevalence of cardiovascular disease. Successful expansion in the U.S. could significantly boost CVRx's revenue and market share.
• European Market Growth: CVRx can capitalize on growth opportunities in Europe by expanding its sales and distribution network in key markets such as Germany and other European countries. This includes establishing relationships with local distributors, participating in medical conferences, and conducting clinical trials to demonstrate the efficacy of Barostim in European patient populations. The European market for heart failure devices is also significant, offering substantial growth potential for CVRx.
• New Clinical Applications: CVRx can explore new clinical applications for its Barostim technology beyond heart failure, such as hypertension and other cardiovascular conditions. This involves conducting clinical research to evaluate the safety and efficacy of Barostim in these new indications. Successful expansion into new clinical applications could broaden CVRx's market reach and revenue streams. The timeline for this growth opportunity depends on the successful completion of clinical trials and regulatory approvals.
• Strategic Partnerships: CVRx can pursue strategic partnerships with larger medical device companies or pharmaceutical companies to leverage their resources and expertise in marketing, sales, and distribution. This could accelerate the adoption of Barostim and expand CVRx's market reach. Potential partners could include companies with established cardiovascular product portfolios or those seeking to enter the neuromodulation space. The timeline for this growth opportunity depends on identifying and securing suitable partnerships.
• Technological Advancements: CVRx can invest in research and development to enhance the capabilities of its Barostim technology and develop next-generation neuromodulation devices. This includes improving the device's ease of use, expanding its functionality, and reducing its size. Technological advancements could differentiate CVRx's products from competitors and attract new customers. The timeline for this growth opportunity depends on the pace of technological innovation and the availability of funding for research and development.

What Opportunities Does CVRX Have?

• Expansion into new clinical applications.
• Strategic partnerships with larger medical device companies.
• Increased adoption of Barostim by cardiologists.
• Growth in emerging markets.

What Threats Does CVRX Face?

• Competition from established medical device companies.
• Regulatory hurdles and reimbursement challenges.
• Potential for technological obsolescence.
• Economic downturns affecting healthcare spending.

What Are CVRX's Competitive Advantages?

• Proprietary Barostim technology with patent protection.
• Specialized expertise in neuromodulation for cardiovascular diseases.
• Established relationships with key opinion leaders in cardiology.
• Regulatory approvals for Barostim in the United States and Europe.

What Does CVRX Do?

CVRx, Inc., established in 2000 and headquartered in Minneapolis, Minnesota, is a commercial-stage medical device company dedicated to developing, manufacturing, and commercializing innovative neuromodulation solutions for individuals with cardiovascular diseases. The company's flagship product, Barostim, is a neuromodulation device specifically designed to alleviate symptoms in patients diagnosed with heart failure (HF) characterized by reduced ejection fraction, also known as systolic HF. Barostim works by stimulating the baroreceptors in the carotid artery, which in turn modulates the autonomic nervous system to improve heart function. CVRx markets and sells its products through a combination of direct sales teams, sales agents, and independent distributors. This multifaceted approach allows the company to reach healthcare providers and patients across the United States, Germany, the rest of Europe, and other international markets. CVRx's focus on neuromodulation represents a targeted approach to addressing cardiovascular conditions, positioning it within a specialized segment of the broader medical device industry.

What Products and Services Does CVRX Offer?

• Develops neuromodulation solutions for cardiovascular diseases.
• Manufactures the Barostim device for heart failure patients.
• Commercializes Barostim through direct sales and distribution networks.
• Targets patients with heart failure with reduced ejection fraction.
• Offers a therapy to improve symptoms of systolic heart failure.
• Sells products in the United States, Germany, and other international markets.

How Does CVRX Make Money?

• Sells Barostim devices to hospitals and clinics.
• Generates revenue through direct sales force and distributors.
• Focuses on reimbursement from healthcare providers and insurance companies.

What Industry Does CVRX Operate In?

CVRx, Inc. operates within the medical device industry, specifically targeting the cardiovascular segment with its neuromodulation technology. The market for heart failure devices is driven by the increasing prevalence of cardiovascular diseases globally. Competition includes established medical device companies and emerging players in neuromodulation. CVRx's Barostim device addresses a specific need in heart failure management, positioning it within a niche market with potential for growth as adoption increases and clinical evidence supports its efficacy.

Who Are CVRX's Key Customers?

• Hospitals and clinics specializing in cardiology.
• Cardiologists and heart failure specialists.
• Patients diagnosed with heart failure with reduced ejection fraction.

FY2026 estForward Outlook

Wall Street analysts project CVRx, Inc. revenue of about $65.3M for fiscal 2026, with EPS near $-1.96. The estimate reflects 5 contributing analysts.

Quarterly Financial Performance: CVRx, Inc.

Revenue for CVRx, Inc. came in at $14.8M during Q1 2026, a 7.8% contraction versus the preceding quarter. The company recorded a net loss of $13.1M, with diluted EPS of $-0.50. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CVRX averaged $-0.51 in diluted EPS.

CVRX Valuation & Market Position

With a $149.40M market cap, CVRx, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CVRX's quantitative score of 16/100 is below the peer average of 69/100.

Key Financial Metrics

Return on assets is -52.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.20 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -38.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

CVRx, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.12 places it in the distress zone, a signal of elevated financial risk.

Company Profile

CVRx, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO Kevin Hykes. CVRX has traded publicly since 2021.

CVRX Financials

CVRX Latest News

CVRX Analyst Consensus

CVRX MoonshotScore

Latest CVRx, Inc. Analysis

What Investors Ask About CVRx, Inc. (CVRX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources